Complement is developing therapeutics that are aimed at systemic modulation of the complement system to address unmet needs in a range of diseases related to complement dysregulation.

Complement’s lead asset CTx001 is currently in pre-clinical development as an AAV based gene therapy for the treatment of Geographic Atrophy (late dry age-related macular degeneration).